Prospective Analysis of Morbi-mortality of Patients With Cancers in Active Phase of Treatment Suspected or Diagnosed of a SARS-CoV-2 Infection

Inclusion Criteria:

I1. Confirmed diagnosis of any type of solid or hematologic tumor;

I2. Ongoing anticancer treatment (cytotoxic, targeted therapy, immunotherapy or loco
regional procedure, including radiotherapy, surgery or interventional radiology procedure)
at the time of inclusion or within the last 3 months prior to inclusion (last treatment
administration or last loco regional procedure) ;

I3. Patient with suspicion of COVID-19 (clinical symptoms of COVID-19 including fever
(>38°C) and/or respiratory tract symptoms), either confirmed or not.

Note 1: Patients must have underwent diagnostic procedures: diagnostic test (positive or
negative) and/or chest imaging. Note 2: Patients will be eligible regardless of the
presence of a neutropenia (either febrile or not) ;

I4. Patient and/or family did not decline data collection after complete information.